tirzepatide creatinine Kidney Parameters with in Obesity... : Journal of the American Society of Nephrology Starting Reta: My Journey with

Implications for Obesity Treatment Policy Tirzepatide appears to be a cost-effective option with favorable modeled clinical outcomes compared to semaglutide for managing obesity and overweight in the U.S

For fat loss research or calorie-restricted protocols, it's a significant confounding variable

Tirzepatide does not directly cause muscle loss, but the calorie deficit it creates can lead to lean mass reduction

1 Key results: Average weight loss: -14.9% of body weight (vs -2.4% with placebo) 86.4% achieved at least 5% weight loss 69.1% achieved at least 10% weight loss 50.5% achieved at least 15% weight loss Wegovy 7.2 mg: the STEP UP trial The STEP UP trial compared semaglutide 7.2 mg with the standard 2.4 mg dose in adults with obesity over 72 weeks